Selexis CHO Cells in Suspension-1

Archives 2011

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

OCTOBER 20, 2011
1 min read

Selexis SA to Present and Partner at the BIO-Europe 2011 Partnering Conference

Dr. Igor Fisch to Present in the Discovery Platform Track

Geneva, Switzerland (PRNEWSWIRE) October 20, 2011 – Selexis...

Read More
OCTOBER 1, 2011
1 min read

Selexis SA to Present Technology Platform Data at the 2011 BioProcess International Convention

Geneva, Switzerland (PRNEWSWIRE) October 21, 2011 – Selexis SA announced today data from the Company’s SUREtechnology...

Read More
SEPTEMBER 27, 2011
3 min read

Selexis SA Forms Scientific Advisory Board Headed by Sir Gregory Winter

Experts will Drive the Company’s Technology Development for Drug Discovery

Geneva, Switzerland (PRNEWSWIRE) September...

Read More
AUGUST 31, 2011
1 min read

Selexis SA CSO to Speak at the Human Antibodies and Hybridomas 2011 Conference

Dr. Pierre-Allain Girod to Present on Data on Engineering CHO Cell Lines for Enhanced Production of Monoclonal...

Read More
JULY 26, 2011
1 min read

CSL Limited Signs Commercial License Agreement with Selexis SA

CSL Limited Signs Commercial License Agreement with Selexis SCSL Limited will use Selexis Technologies for Development...

Read More
JULY 13, 2011
1 min read

Selexis CEO Elected to Board of Affitech A/S

Geneva, Switzerland (PRWEB) July 13, 2011 – Selexis SA, a global life science company with technologies for drug...

Read More
JUNE 27, 2011
1 min read

Selexis SA CEO to Speak at the GEN Drug Discovery Theater at BIO 2011

Dr. Igor Fisch to Present Data on Company’s New Designer CHO Cell Lines Developed to Overcome Protein Expression...

Read More
JUNE 24, 2011
2 min read

Selexis SA to Give Away € 25,000 SUREvariant Screening Service Project at BIO 2011

Celebrating Launch of New Service in Support of Biologic Lead Identification

Geneva, Switzerland (PRWEB) June 24, 2011...

Read More
APRIL 20, 2011
1 min read

Selexis SA to Speak on Fc Fusion Proteins at the 2011 European Society for Animal Cell Technology (ESACT) Conference

Selexis to Meet with Companies Interested in Mammalian Cell Line Development, Lead Identification for Therapeutic Drug...

Read More
APRIL 19, 2011
1 min read

Selexis SA to Speak on Rapidly Identifying Relevant Monoclonal Antibody Variants at the 2011 Protein Engineering (PEGS) Summit

Geneva, Switzerland (PRWEB) April 19, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the...

Read More
MARCH 23, 2011
2 min read

Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome

Major Milestone Will Speed Regulatory Filings for Recombinant Protein Therapeutics and Monoclonal Antibodies Developed...

Read More
MARCH 11, 2011
1 min read

Selexis SA to Partner at the BIO-Europe Spring 2011 Partnering Conference

Geneva, Switzerland (PRWEB) March 11, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the...

Read More
MARCH 9, 2011
2 min read

Selexis SA Celebrates 10 Years of Innovative Technologies for Mammalian Cells Lines Used in Protein Manufacturing

Geneva, Switzerland (PRWEB) March 9, 2011 – Selexis SA, a Swiss-based biotechnology company with technologies for the...

Read More
MARCH 8, 2011
2 min read

Selexis SA Launches the SURE Variant Screening Service

New Service Will Speed Library Screening Campaigns

Geneva, Switzerland (PRWEB) March 08, 2011 – Selexis SA, a...

Read More
FEBRUARY 9, 2011
1 min read

Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland

Major Expansion Includes Protein Purification Unit

Geneva, Switzerland (PRWEB) February 9, 2011, Selexis SA, a...

Read More
JANUARY 5, 2011
1 min read

Selexis and Neogenix Oncology Execute Commercial License Agreement

Geneva, Switzerland, January 5, 2011 Selexis SA, a Swiss-based biotechnology company offering technologies and services...

Read More
Selexis CHO cells high expressing mAB bispecific antibody
 

Driven by Excellence. Guided by Science.


Connect with us.
From ubiquitous immunoglobulin-based drugs such as monoclonal and bispecific antibodies and Fc Fusions to novel scaffolds and difficult-to-express proteins, Selexis is your partner of choice

 

 

Connect with Us

 

Explore the SUREtechnology Platform™

Selexis Monoclonal Antibodies block

Monoclonal Antibodies

For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving monoclonal antibodies through all the steps from IND filling, clinical phases, to market launch and commericialization.

Learn More
Selexis Difficult-to-Express Proteins block

Difficult-to-Express Proteins

At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.

Learn More
Selexis Bispecific Antibodies block

Bispecific Antibodies

We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.

Learn More
Selexis SA footer Logo

Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

 

A JSR Life Sciences Company Logo
EN-BEST MEDIUM WORKPLACES_CMYK

Latest News

October 31, 2022

KBI Biopharma, Inc. and Selexis SA Expand Executive Leadership Team with the Appointment of Abdelaziz Toumi, Ph.D. as Chief Business Officer

Read More
September 8, 2022

Selexis and NexImmune Sign Service Agreement to Advance Multiple Immunotherapies Targeting Rare Cancers and Autoimmune Disorders

Read More

Copyright© 2023 Selexis SA. All Rights Reserved.